121 related articles for article (PubMed ID: 30547188)
1. Successful retreatment with 3-week rituximab-bendamustine with high-dose dexamethasone in patients with relapsed/refractory mantle cell lymphoma.
Lamm W; Kiesewetter B; Puhr H; Dolak W; Mayerhöfer ME; Raderer M
Ann Hematol; 2019 Jun; 98(6):1519-1520. PubMed ID: 30547188
[No Abstract] [Full Text] [Related]
2. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.
Rummel M; Kaiser U; Balser C; Stauch M; Brugger W; Welslau M; Niederle N; Losem C; Boeck HP; Weidmann E; von Gruenhagen U; Mueller L; Sandherr M; Hahn L; Vereshchagina J; Kauff F; Blau W; Hinke A; Barth J;
Lancet Oncol; 2016 Jan; 17(1):57-66. PubMed ID: 26655425
[TBL] [Abstract][Full Text] [Related]
3. Influence of rituximab plus bendamustine chemotherapy on the immune system in patients with refractory or relapsed follicular lymphoma and mantle cell lymphoma.
Ito K; Okamoto M; Ando M; Kakumae Y; Okamoto A; Inaguma Y; Tokuda M; Yanada M; Yamada S; Emi N
Leuk Lymphoma; 2015 Apr; 56(4):1123-5. PubMed ID: 24828861
[No Abstract] [Full Text] [Related]
4. Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi.
Zaja F; Ferrero S; Stelitano C; Ferrari A; Salvi F; Arcari A; Musuraca G; Botto B; Spina M; Cellini C; Patti C; Liberati AM; Minotto C; Pileri SA; Ceccarelli M; Volpetti S; Ferranti A; Drandi D; Montechiarello E; Ladetto M; Carmichael J; Fanin R
Haematologica; 2017 May; 102(5):e203-e206. PubMed ID: 28082342
[No Abstract] [Full Text] [Related]
5. Combined rituximab, bendamustine, and dexamethasone chemotherapy for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma: a multicenter phase II study.
Matsumoto Y; Kobayashi T; Shimura Y; Kawata E; Nagoshi H; Ohshiro M; Sugitani M; Shimura K; Iwai T; Fuchida SI; Yoshida M; Kiyota M; Mizutani S; Chinen Y; Takimoto-Shimomura T; Nakao M; Kaneko H; Uchiyama H; Uoshima N; Nishigaki H; Kobayashi Y; Horiike S; Shimazaki C; Taniwaki M; Kuroda J;
Int J Hematol; 2019 Jul; 110(1):77-85. PubMed ID: 31127456
[TBL] [Abstract][Full Text] [Related]
6. Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma.
Saito H; Maruyama D; Maeshima AM; Makita S; Kitahara H; Miyamoto K; Fukuhara S; Munakata W; Suzuki T; Kobayashi Y; Taniguchi H; Tobinai K
Blood Cancer J; 2015 Oct; 5(10):e362. PubMed ID: 26495859
[No Abstract] [Full Text] [Related]
7. Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a multicenter retrospective analysis.
Hong JY; Yoon DH; Suh C; Kim WS; Kim SJ; Jo JC; Kim JS; Lee WS; Oh SY; Park Y; Kim SY; Lee MH; Lee HS; Do YR
Ann Hematol; 2018 Aug; 97(8):1437-1443. PubMed ID: 29619501
[TBL] [Abstract][Full Text] [Related]
8. A rare composite lymphoma: follicular and in situ mantle cell.
Marí-Jimenez P; Martínez-Losada C; Centeno-Haro M; Rodríguez-García G; Perez-Seoane C; Sánchez-García J
Ann Hematol; 2016 Aug; 95(8):1351-2. PubMed ID: 27103006
[No Abstract] [Full Text] [Related]
9. Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings.
Czuczman MS; Goy A; Lamonica D; Graf DA; Munteanu MC; van der Jagt RH
Ann Hematol; 2015 Dec; 94(12):2025-32. PubMed ID: 26411584
[TBL] [Abstract][Full Text] [Related]
10. Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies.
Awan FT; Gore L; Gao L; Sharma J; Lager J; Costa LJ
Br J Haematol; 2016 Oct; 175(1):55-65. PubMed ID: 27293194
[TBL] [Abstract][Full Text] [Related]
11. Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma: A Phase I Trial.
Kambhampati S; Fakhri B; Ai WZ; Kaplan LD; Tuscano JM; Wieduwilt MJ; Sudhindra A; Cavallone E; Reiner J; Aoun C; Castillo M; Martinelli M; Ta T; Le D; Padilla M; Crawford E; Andreadis CB
Clin Lymphoma Myeloma Leuk; 2021 Mar; 21(3):139-146. PubMed ID: 33478921
[TBL] [Abstract][Full Text] [Related]
12. A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma.
Gressin R; Daguindau N; Tempescul A; Moreau A; Carras S; Tchernonog E; Schmitt A; Houot R; Dartigeas C; Pignon JM; Corm S; Banos A; Mounier C; Dupuis J; Macro M; Fleury J; Jardin F; Sarkozy C; Damaj G; Feugier P; Fornecker LM; Chabrot C; Dorvaux V; Bouadallah K; Amorin S; Garidi R; Voillat L; Joly B; Celigny PS; Morineau N; Moles MP; Zerazhi H; Fontan J; Arkam Y; Alexis M; Delwail V; Vilque JP; Ysebaert L; Le Gouill S; Callanan MB;
Haematologica; 2019 Jan; 104(1):138-146. PubMed ID: 30171024
[TBL] [Abstract][Full Text] [Related]
13. Retrospective analysis of bendamustine and rituximab use in indolent and mantle cell non-Hodgkin lymphoma based on initial starting dose.
Bond DA; Huang Y; Ruppert AS; Walker AR; Dotson EK; Roddy J; Blum KA; Christian BA
Leuk Lymphoma; 2017 Jul; 58(7):1589-1597. PubMed ID: 27838951
[TBL] [Abstract][Full Text] [Related]
14. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).
Weide R; Hess G; Köppler H; Heymanns J; Thomalla J; Aldaoud A; Losem C; Schmitz S; Haak U; Huber C; Unterhalt M; Hiddemann W; Dreyling M;
Leuk Lymphoma; 2007 Jul; 48(7):1299-306. PubMed ID: 17613757
[TBL] [Abstract][Full Text] [Related]
15. Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma.
Sivaraj D; Green MM; Kang Y; Long GD; Rizzieri DA; Li Z; Garrett AH; McIntyre JL; Chao NJ; Gasparetto C
Blood Cancer J; 2018 Jul; 8(8):71. PubMed ID: 30065277
[No Abstract] [Full Text] [Related]
16. A case of "double hit" mantle cell lymphoma carrying CCND1 and MYC translocations relapsed/refractory to rituximab bendamustine cytarabine (R-BAC) and ibrutinib.
Scapinello G; Riva M; Branca A; Pizzi M; Bonaldi L; Martines A; Manni S; Visentin A; Trentin L; Semenzato G; Gurrieri C; Piazza F
Ann Hematol; 2020 Nov; 99(11):2715-2717. PubMed ID: 32671454
[No Abstract] [Full Text] [Related]
17. Bendamustine and G-CSF support.
Imataki O; Uchida S; Yokokura S; Uemura M; Kadowaki N
Support Care Cancer; 2019 May; 27(5):1581-1582. PubMed ID: 29484498
[No Abstract] [Full Text] [Related]
18. Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi.
Visco C; Chiappella A; Nassi L; Patti C; Ferrero S; Barbero D; Evangelista A; Spina M; Molinari A; Rigacci L; Tani M; Rocco AD; Pinotti G; Fabbri A; Zambello R; Finotto S; Gotti M; Carella AM; Salvi F; Pileri SA; Ladetto M; Ciccone G; Gaidano G; Ruggeri M; Martelli M; Vitolo U
Lancet Haematol; 2017 Jan; 4(1):e15-e23. PubMed ID: 27927586
[TBL] [Abstract][Full Text] [Related]
19. Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas.
Ahmadi T; Chong EA; Gordon A; Aqui NA; Nasta SD; Svoboda J; Mato AR; Schuster SJ
Cancer; 2014 Jan; 120(2):222-8. PubMed ID: 24122387
[TBL] [Abstract][Full Text] [Related]
20. Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma.
Kamdar M; Li H; Chen RW; Rimsza LM; Leblanc ML; Fenske TS; Shea TC; Barr PM; Phillips TJ; Leonard JP; Kahl BS; Friedberg JW; Smith SM
Blood Adv; 2019 Oct; 3(20):3132-3135. PubMed ID: 31648328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
